213 related articles for article (PubMed ID: 19551676)
1. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma.
Hasanreisoglu M; Weinberger D; Mimouni K; Luski M; Bourla D; Kramer M; Robinson A; Axer-Siegel R
Eur J Ophthalmol; 2009; 19(4):607-12. PubMed ID: 19551676
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
3. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab.
Lupinacci AP; Calzada JI; Rafieetery M; Charles S; Netland PA
Adv Ther; 2009 Feb; 26(2):208-16. PubMed ID: 19234680
[TBL] [Abstract][Full Text] [Related]
5. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Batioğlu F; Astam N; Ozmert E
Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous intravitreal and intracameral injection of bevacizumab (Avastin) in neovascular glaucoma.
Yuzbasioglu E; Artunay O; Rasier R; Sengul A; Bahcecioglu H
J Ocul Pharmacol Ther; 2009 Jun; 25(3):259-64. PubMed ID: 19348598
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab.
Moraczewski AL; Lee RK; Palmberg PF; Rosenfeld PJ; Feuer WJ
Br J Ophthalmol; 2009 May; 93(5):589-93. PubMed ID: 19074917
[TBL] [Abstract][Full Text] [Related]
8. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma.
Higashide T; Murotani E; Saito Y; Ohkubo S; Sugiyama K
Graefes Arch Clin Exp Ophthalmol; 2012 Apr; 250(4):603-10. PubMed ID: 22116499
[TBL] [Abstract][Full Text] [Related]
9. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients.
Duch S; Buchacra O; Milla E; Andreu D; Tellez J
J Glaucoma; 2009 Feb; 18(2):140-3. PubMed ID: 19225351
[TBL] [Abstract][Full Text] [Related]
10. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C.
Alkawas AA; Shahien EA; Hussein AM
J Glaucoma; 2010 Dec; 19(9):622-6. PubMed ID: 20179624
[TBL] [Abstract][Full Text] [Related]
11. Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin) in neovascular glaucoma.
Ghosh S; Singh D; Ruddle JB; Shiu M; Coote MA; Crowston JG
Clin Exp Ophthalmol; 2010 May; 38(4):353-7. PubMed ID: 20665941
[TBL] [Abstract][Full Text] [Related]
12. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.
Lüke J; Nassar K; Lüke M; Grisanti S
Graefes Arch Clin Exp Ophthalmol; 2013 Oct; 251(10):2403-13. PubMed ID: 23893090
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion.
Vatavuk Z; Bencic G; Mandic Z
Eur J Ophthalmol; 2007; 17(2):269-71. PubMed ID: 17415704
[TBL] [Abstract][Full Text] [Related]
14. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.
Ehlers JP; Spirn MJ; Lam A; Sivalingam A; Samuel MA; Tasman W
Retina; 2008 May; 28(5):696-702. PubMed ID: 18463512
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.
Yazdani S; Hendi K; Pakravan M; Mahdavi M; Yaseri M
J Glaucoma; 2009; 18(8):632-7. PubMed ID: 19826393
[TBL] [Abstract][Full Text] [Related]
16. Role of intravitreal bevacizumab in neovascular glaucoma.
Gheith ME; Siam GA; de Barros DS; Garg SJ; Moster MR
J Ocul Pharmacol Ther; 2007 Oct; 23(5):487-91. PubMed ID: 17900231
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up.
Costagliola C; Cipollone U; Rinaldi M; della Corte M; Semeraro F; Romano MR
Br J Clin Pharmacol; 2008 Nov; 66(5):667-73. PubMed ID: 19032174
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.
Falavarjani KG; Modarres M; Nazari H
Eye (Lond); 2010 Apr; 24(4):717-9. PubMed ID: 19407842
[TBL] [Abstract][Full Text] [Related]
19. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma.
Silva Paula J; Jorge R; Alves Costa R; Rodrigues Mde L; Scott IU
Acta Ophthalmol Scand; 2006 Aug; 84(4):556-7. PubMed ID: 16879583
[No Abstract] [Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
Iliev ME; Domig D; Wolf-Schnurrbursch U; Wolf S; Sarra GM
Am J Ophthalmol; 2006 Dec; 142(6):1054-6. PubMed ID: 17157590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
